Cargando…

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2

The evaluation of the neutralizing capacity of anti-SARS-CoV-2 antibodies is important because they represent real protective immunity. In this study we aimed to measure and compare the neutralizing antibodies (NAbs) in COVID-19 patients and in vaccinated individuals. One-hundred and fifty long-term...

Descripción completa

Detalles Bibliográficos
Autores principales: Favresse, Julien, Gillot, Constant, Di Chiaro, Laura, Eucher, Christine, Elsen, Marc, Van Eeckhoudt, Sandrine, David, Clara, Morimont, Laure, Dogné, Jean-Michel, Douxfils, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309994/
https://www.ncbi.nlm.nih.gov/pubmed/34372570
http://dx.doi.org/10.3390/v13071364
_version_ 1783728654060093440
author Favresse, Julien
Gillot, Constant
Di Chiaro, Laura
Eucher, Christine
Elsen, Marc
Van Eeckhoudt, Sandrine
David, Clara
Morimont, Laure
Dogné, Jean-Michel
Douxfils, Jonathan
author_facet Favresse, Julien
Gillot, Constant
Di Chiaro, Laura
Eucher, Christine
Elsen, Marc
Van Eeckhoudt, Sandrine
David, Clara
Morimont, Laure
Dogné, Jean-Michel
Douxfils, Jonathan
author_sort Favresse, Julien
collection PubMed
description The evaluation of the neutralizing capacity of anti-SARS-CoV-2 antibodies is important because they represent real protective immunity. In this study we aimed to measure and compare the neutralizing antibodies (NAbs) in COVID-19 patients and in vaccinated individuals. One-hundred and fifty long-term samples from 75 COVID-19 patients were analyzed with a surrogate virus neutralization test (sVNT) and compared to six different SARS-CoV-2 serology assays. The agreement between the sVNT and pseudovirus VNT (pVNT) results was found to be excellent (i.e., 97.2%). The NAb response was also assessed in 90 individuals who had received the complete dose regimen of BNT162b2. In COVID-19 patients, a stronger response was observed in moderate–severe versus mild patients (p-value = 0.0006). A slow decay in NAbs was noted in samples for up to 300 days after diagnosis, especially in moderate–severe patients (r = −0.35, p-value = 0.03). In the vaccinated population, 83.3% of COVID-19-naive individuals had positive NAbs 14 days after the first dose and all were positive 7 days after the second dose, i.e., at day 28. In previously infected individuals, all were already positive for NAbs at day 14. At each time point, a stronger response was observed for previously infected individuals (p-value < 0.05). The NAb response remained stable for up to 56 days in all participants. Vaccinated participants had significantly higher NAb titers compared to COVID patients. In previously infected vaccine recipients, one dose might be sufficient to generate sufficient neutralizing antibodies.
format Online
Article
Text
id pubmed-8309994
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83099942021-07-25 Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2 Favresse, Julien Gillot, Constant Di Chiaro, Laura Eucher, Christine Elsen, Marc Van Eeckhoudt, Sandrine David, Clara Morimont, Laure Dogné, Jean-Michel Douxfils, Jonathan Viruses Article The evaluation of the neutralizing capacity of anti-SARS-CoV-2 antibodies is important because they represent real protective immunity. In this study we aimed to measure and compare the neutralizing antibodies (NAbs) in COVID-19 patients and in vaccinated individuals. One-hundred and fifty long-term samples from 75 COVID-19 patients were analyzed with a surrogate virus neutralization test (sVNT) and compared to six different SARS-CoV-2 serology assays. The agreement between the sVNT and pseudovirus VNT (pVNT) results was found to be excellent (i.e., 97.2%). The NAb response was also assessed in 90 individuals who had received the complete dose regimen of BNT162b2. In COVID-19 patients, a stronger response was observed in moderate–severe versus mild patients (p-value = 0.0006). A slow decay in NAbs was noted in samples for up to 300 days after diagnosis, especially in moderate–severe patients (r = −0.35, p-value = 0.03). In the vaccinated population, 83.3% of COVID-19-naive individuals had positive NAbs 14 days after the first dose and all were positive 7 days after the second dose, i.e., at day 28. In previously infected individuals, all were already positive for NAbs at day 14. At each time point, a stronger response was observed for previously infected individuals (p-value < 0.05). The NAb response remained stable for up to 56 days in all participants. Vaccinated participants had significantly higher NAb titers compared to COVID patients. In previously infected vaccine recipients, one dose might be sufficient to generate sufficient neutralizing antibodies. MDPI 2021-07-14 /pmc/articles/PMC8309994/ /pubmed/34372570 http://dx.doi.org/10.3390/v13071364 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Favresse, Julien
Gillot, Constant
Di Chiaro, Laura
Eucher, Christine
Elsen, Marc
Van Eeckhoudt, Sandrine
David, Clara
Morimont, Laure
Dogné, Jean-Michel
Douxfils, Jonathan
Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
title Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
title_full Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
title_fullStr Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
title_full_unstemmed Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
title_short Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
title_sort neutralizing antibodies in covid-19 patients and vaccine recipients after two doses of bnt162b2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309994/
https://www.ncbi.nlm.nih.gov/pubmed/34372570
http://dx.doi.org/10.3390/v13071364
work_keys_str_mv AT favressejulien neutralizingantibodiesincovid19patientsandvaccinerecipientsaftertwodosesofbnt162b2
AT gillotconstant neutralizingantibodiesincovid19patientsandvaccinerecipientsaftertwodosesofbnt162b2
AT dichiarolaura neutralizingantibodiesincovid19patientsandvaccinerecipientsaftertwodosesofbnt162b2
AT eucherchristine neutralizingantibodiesincovid19patientsandvaccinerecipientsaftertwodosesofbnt162b2
AT elsenmarc neutralizingantibodiesincovid19patientsandvaccinerecipientsaftertwodosesofbnt162b2
AT vaneeckhoudtsandrine neutralizingantibodiesincovid19patientsandvaccinerecipientsaftertwodosesofbnt162b2
AT davidclara neutralizingantibodiesincovid19patientsandvaccinerecipientsaftertwodosesofbnt162b2
AT morimontlaure neutralizingantibodiesincovid19patientsandvaccinerecipientsaftertwodosesofbnt162b2
AT dognejeanmichel neutralizingantibodiesincovid19patientsandvaccinerecipientsaftertwodosesofbnt162b2
AT douxfilsjonathan neutralizingantibodiesincovid19patientsandvaccinerecipientsaftertwodosesofbnt162b2